A Pilot Study of Modafinil for Treatment of Fatigue and Neurobehavioral Dysfunction in Adult Brain Tumor Patients
- Compare the effectiveness of low-dose vs high-dose modafinil for treatment of fatigue
and neurobehavioral dysfunction in patients with primary brain tumors.
- Determine the safety of this drug in these patients.
- Compare quality of life of patients treated with 2 different doses of this drug.
OUTLINE: This is a randomized, double-blind, parallel-group study. Patients are randomized
to 1 of 2 arms.
- Randomized phase:
- Arm I: Patients receive oral high-dose modafinil twice daily.
- Arm II: Patients receive oral low-dose modafinil twice daily. In both arms,
treatment in this phase continues for 3 weeks followed by a 1-week washout period.
- Extended treatment phase:After the 1-week washout period, all patients receive oral
low-dose modafinil once daily on days 1-3. The dose is then titrated to an optimal
level and administered in divided doses.
Fatigue, neurobehavioral dysfunction, and quality of life are assessed during the randomized
phase at baseline and on days 7 and 21 and then during the extended treatment phase at
baseline and on days 28 and 56.
PROJECTED ACCRUAL: Approximately 30 patients will be accrued for this study.
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
at baseline and weeks 1, 3, 4, 8, and 10
Timothy F. Cloughesy, MD
Jonsson Comprehensive Cancer Center
United States: Institutional Review Board
|Jonsson Comprehensive Cancer Center at UCLA||Los Angeles, California 90095-1781|